Vibostolimab/Favezelimab Clinical Programs in NSCLC/Lymphoma Discontinued
Clinical development programs including the KeyVibe program investigating the anti–TIGIT antibody vibostolimab and the KEYFORM program investigating the anti–LAG-3 agent favezelimab have been discontinued, according to a press release from the developer, …